Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901677 | 0.80 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBPARP1 | |
| SCHEMBL4569748 | 0.80 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBNPC1 | |
| SCHEMBL29538937 | 0.80 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBPARP1 | |
| SCHEMBL4572243 | 0.77 | HCAR1 (0.38) | PI4KAPI4K2BPI4K2API4KBHCAR1 | |
| SCHEMBL128435 | 0.75 | DDB1 (0.42) | CYP17A1KDM4EALDH1A1CYP1A2MEN1 | |
| SCHEMBL10014711 | 0.74 | MEN1 (0.39) | PI4KAPI4K2BPI4K2API4KBNPC1 | |
| SCHEMBL20471908 | 0.73 | TLR8 (0.37) | PI4KAPI4K2BPI4K2API4KBPARP1 | |
| SCHEMBL15907143 | 0.73 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBNPC1 | |
| SCHEMBL3424861 | 0.73 | PARP15 (0.38) | PARP1CYP17A1AURKACYP1A2 | |
| SCHEMBL3425500 | 0.73 | CYP17A1 (0.36) | PARP1CYP17A1ALDH1A1SMN1; SMN2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20190048344-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2019-02-14 | — | — | US | disclosed |
| US-9914924-B2 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2018-03-13 | — | — | US | disclosed |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070275914-A1 | Therapeutic Compositions | BANK OF AMERICA, N.A. | 2007-11-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | NSUN2, RNGTT, DCLRE1B | PI4KA 3279/4885PI4K2B 2847/4885PI4K2A 2747/4885 |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | PI4KA 2920/4885PI4K2B 2760/4885PI4K2A 1658/4885 |
| US-20190048344-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | PI4KA 2090/4885PI4K2B 2675/4885PI4K2A 2423/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | PI4KA 2851/4885PI4K2B 3299/4885PI4K2A 2829/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PI4KA 1611/4885PI4K2B 2041/4885PI4K2A 1481/4885 |
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | PI4KA 3564/4885PI4K2B 2704/4885PI4K2A 1607/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | PI4KA 2747/4885PI4K2B 2464/4885PI4K2A 2097/4885 |
| US-20070275914-A1 | Therapeutic Compositions | AGO2, EXOSC5, RNASE1 | PI4KA 3450/4885PI4K2B 3030/4885PI4K2A 2909/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | PI4KA 1611/4885PI4K2B 2041/4885PI4K2A 1481/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | PI4KA 2747/4885PI4K2B 2464/4885PI4K2A 2097/4885 |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | LDLR, RNASE1, SARNP | PI4KA 1808/4885PI4K2B 2264/4885PI4K2A 1725/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | PI4KA 1611/4885PI4K2B 2041/4885PI4K2A 1481/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | PI4KA 3823/4885PI4K2B 3811/4885PI4K2A 3642/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | PI4KA 3515/4885PI4K2B 3653/4885PI4K2A 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.